Therapicon Srl

Go to content

Antimetastatic effect on human cell disorders

Method for using recombinant human lysozyme (rHLys) from genetic engineering to control life-threatening diseases associated with abnormal cell proliferation and migration, such as cancer metastasis, by administering therapeutically effective doses of recombinant human lysozyme to elicit said antimetastatic effects.

® is a registered trade-mark in Italy and at OMPI (WIPO)-Geneva

Copyright 2008-2012 - Therapicon Srl - Vat Nr.: IT08071680154 - Phone: +39 02 433042 - Fax: +39 02 48195224 |

Back to content | Back to main menu